Research programme: lung cancer therapeutics - OncoTherapy Science/Yakult Honsha
Latest Information Update: 27 Nov 2007
At a glance
- Originator OncoTherapy Science; Yakult Honsha
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 03 May 2004 Preclinical trials in Lung cancer in Japan (unspecified route)